Related Experiment Video

Updated: Jun 19, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
12:38

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Published on: July 19, 2007

How a US regulator can encourage new science

D C Throckmorton1

  • 1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. douglas.throckmorton@fda.hhs.gov

Clinical Pharmacology and Therapeutics
|October 22, 2009
PubMed

Insights

The US Food and Drug Administration is developing a process for qualifying biomarkers. This study details the formal qualification of novel biomarkers for acute renal toxicity in animals, emphasizing collaboration and regulatory roles.

Area of Science:

  • Biomarker Discovery and Development
  • Toxicology and Drug Safety
  • Regulatory Science

Background:

  • The Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) is establishing a formal process for biomarker qualification.
  • Biomarkers are crucial for assessing drug safety and efficacy, particularly in preclinical studies.
  • Formal qualification ensures biomarkers meet specific standards for use in regulatory decision-making.

Discussion:

  • Goodsaid et al. present their work on the formal qualification of novel biomarkers for acute renal toxicity in animal models.
  • The study highlights the practical challenges and considerations in the biomarker qualification process.
  • Effective collaboration between researchers and regulatory agencies is essential for successful biomarker qualification.

Key Insights:

  • Novel biomarkers for acute renal toxicity have undergone a formal qualification process.
  • The experiences underscore the critical role of regulatory bodies like the FDA in advancing biomarker science.
  • Successful biomarker qualification relies on rigorous scientific validation and clear regulatory pathways.

Outlook:

  • This work contributes to the broader effort of developing standardized methods for biomarker qualification.
  • The established process and insights gained can inform future biomarker development for various toxicities.
  • Advancements in biomarker qualification will accelerate drug development and enhance patient safety.

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Global Regulatory Systems01:28

Global Regulatory Systems

Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Ethics in Research01:56

Ethics in Research

Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.